# Biomerica, Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Biomerica, Inc). ## Overview Biomerica, Inc. develops and commercializes diagnostic products used in clinical laboratories, physician offices, point-of-care settings, and consumer channels. The company also performs contract manufacturing and certain diagnostic testing services, with manufacturing primarily in the United States and Mexico. Its portfolio includes clinical lab products, OTC diagnostics, and its inFoods® diagnostic-guided therapy platform, which is aimed at gastrointestinal conditions such as IBS. Biomerica sells through distributors and direct channels, and a meaningful portion of revenue comes from international markets. The business is still in a turnaround and commercialization phase, with management focused on expanding distributor relationships and new product adoption while managing liquidity constraints. ## Products & services • Clinical laboratory diagnostic products • inFoods® IBS diagnostic-guided therapy platform • Over-the-counter diagnostic products • Physician office diagnostic products • Contract manufacturing services • Third-party diagnostic testing services • International distributor sales - **Clinical laboratory diagnostics** (55%) — Tests and diagnostic products sold to clinical labs, hospitals, medical research institutions, and distributors. - **Point-of-care and physician office diagnostics** (15%) — Products and services used in patient point-of-care settings and physicians' offices, including direct and distributor sales. - **Over-the-counter diagnostics** (10%) — Consumer-facing diagnostic products sold through drug stores, e-commerce, and distributors. - **Contract manufacturing** (10%) — Manufacturing services performed for third parties, recognized as work is completed or progresses. - **Diagnostic-guided therapy products** (10%) — inFoods®-based products designed to guide treatment for IBS and other inflammatory conditions. - Clinical laboratory diagnostic products - inFoods® IBS diagnostic-guided therapy platform - Over-the-counter diagnostic products - Physician office diagnostic products - Contract manufacturing services - Third-party diagnostic testing services - International distributor sales ## Customers Biomerica sells to a mix of distributors and end users, with clinical laboratories and patient point-of-care testing identified as its two primary target markets. Its customer base includes hospitals, clinical laboratories, medical research institutions, pharmaceutical companies, drugstores, wholesalers, physicians' offices, and e-commerce customers. The company also serves direct patients and physician offices through certain diagnostic testing services that are processed by third-party CLIA-certified laboratories. International distributors are important because management says a significant portion of revenue comes from outside the United States. Customer concentration can be meaningful, as recent filings disclosed a large share of quarterly sales and receivables tied to a small number of customers in Asia, North America, and Europe. - **Clinical laboratories** (primary) — Buy diagnostic products for routine testing and are a primary target because they drive recurring product demand. - **Point-of-care and physician offices** (primary) — Buy rapid diagnostic products and inFoods-related offerings for use in patient-facing settings. - **Distributors** (primary) — Purchase products for resale across domestic and international markets and are critical to market access. - **OTC retail and e-commerce** (secondary) — Buy consumer diagnostic products through drugstores and online channels to reach end users directly. - **Hospitals and medical research institutions** (secondary) — Purchase specialized diagnostics for clinical use, validation, and research applications. - **Pharmaceutical and life sciences customers** (emerging) — Buy diagnostic and contract manufacturing services for development, testing, or commercialization support. - Clinical laboratories buying tests for routine diagnostic workflows - Hospitals and medical institutions purchasing diagnostic products for patient care - Distributors buying in bulk for resale across domestic and international markets - Physicians' offices using point-of-care or specialty diagnostic products - Drugstores and e-commerce customers buying OTC diagnostic products - Pharmaceutical companies and research institutions using specialized diagnostic tools ## Geography Biomerica manufactures primarily in the United States and Mexico, with Biomerica de Mexico operating as a significant manufacturing facility. The company also has BioEurope GmbH and a sales presence in Germany supporting Europe and South America, while management notes relationships across Europe, Eastern Europe, the Middle East, Latin America, Canada, and the United States. A significant portion of revenue is derived from international sales, and the company specifically cites distributors in Europe, China, and other countries as important markets. This geographic mix creates both growth opportunities and operational exposure to currency, regulatory, and cross-border supply chain risk. The company also sources certain raw materials from Asia and other regions, which adds procurement and logistics complexity. - Manufacturing is centered in the United States and Mexico - Biomerica de Mexico is a significant operating and manufacturing site - Germany-based sales leadership supports Europe and South America - International sales are a meaningful part of revenue - Distributor relationships span Europe, Eastern Europe, the Middle East, Latin America, Canada, and the U.S. - Raw materials are sourced from Asia and other regions, creating supply-chain exposure ## Strategy Biomerica's near-term strategy is centered on expanding commercialization of inFoods® IBS and building broader adoption through GI physician groups and other specialties. Management is also pursuing distribution, partnership, and licensing opportunities to scale the product more efficiently in the United States and internationally. At the same time, the company is trying to preserve liquidity by reducing operating expenses, scaling back some R&D programs, and managing headcount after a workforce reduction. International distributor expansion remains important because the company sees growth potential across Europe, Latin America, Canada, and other regions. The strategy is therefore a mix of product commercialization, channel expansion, and cost discipline aimed at improving the odds of reaching sustainable operations. - **Commercialize inFoods® IBS** (short-term) — The product is a key growth driver and a proof point for the company's diagnostic-guided therapy platform. - **Build scalable distribution and licensing partnerships** (medium-term) — Third-party partners can extend market reach without requiring the company to build a large direct sales footprint. - **Maintain liquidity and reduce cash burn** (short-term) — The company has recurring losses and limited cash, so expense control is necessary to fund operations and commercialization. - Expand inFoods® IBS adoption through GI physician groups - Broaden use into other specialties such as integrated health and primary care - Pursue distribution, partnership, and licensing deals to scale commercialization - Grow international distributor coverage in Europe, Latin America, and Canada - Control operating expenses and preserve cash while launching products - Reduce R&D spend where programs have been scaled back or commercialized ## Risks Biomerica faces substantial going-concern and financing risk because it has a history of operating losses, negative operating cash flow, and limited cash resources relative to its operating needs. The company also depends on successful commercialization of new products and international expansion, which may not scale quickly enough to offset cash burn. Its business is exposed to regulatory and certification risk because sales in Europe, China, and other markets require compliance with changing quality and IVDR requirements; failure could disrupt sales or force product withdrawals. Manufacturing in Mexico and sourcing raw materials from Asia create supply-chain, labor, currency, and geopolitical exposure, while customer concentration can make quarterly results volatile when a small number of buyers account for a large share of sales or receivables. As a diagnostics company, it also faces typical industry risks around product performance, reimbursement, distributor dependence, and inventory obsolescence. - **Going-concern and liquidity shortfall** [critical] — Management states current cash is insufficient to meet operating cash requirements and strategic growth objectives over the next twelve months. - **Customer concentration** [high] — A small number of customers accounted for a large share of quarterly sales and receivables, making results sensitive to order timing or loss of a key account. - **Regulatory and certification compliance** [high] — Sales in Europe, China, and other countries depend on maintaining certifications and meeting evolving quality and IVDR requirements. - **Mexico manufacturing disruption** [high] — A significant manufacturing facility is located in Mexico, exposing the company to local economic, political, labor, and import/export risks. - **Commercialization execution risk** [high] — inFoods® and other new products must gain physician adoption and distributor support to generate meaningful revenue. - Going-concern and financing risk due to recurring losses and limited cash - Customer concentration can cause volatile revenue and receivables - Regulatory and certification risk in Europe, China, and other markets - Mexico manufacturing exposes the company to labor, political, and currency risk - Asia sourcing creates supply-chain and input availability risk - Commercialization risk for inFoods® and other new products - Inventory and product obsolescence risk in a small diagnostics portfolio ## Accounting Revenue recognition is a key accounting area because the company sells products, services, and contract manufacturing work using different timing rules. Product sales are generally recognized when shipped FOB shipping point, while diagnostic testing services are recognized when the third-party lab completes the test and contract manufacturing revenue is recognized as services are performed or progress is made. This means quarterly revenue can shift with shipment timing, service completion, and customer ordering patterns, especially given the company's small revenue base and customer concentration. Management also highlights estimates for bad debts, inventory overhead application, inventory reserves, lease liabilities, right-of-use assets, and share-based compensation, all of which can materially affect reported margins and operating results. Because the company has limited liquidity and a history of losses, judgments around collectability, inventory obsolescence, and going-concern assumptions are especially important for investors. - **Revenue recognition timing** — Revenue and gross margin - **Inventory reserves and overhead allocation** — Gross margin and operating income - **Credit loss estimates** — Accounts receivable and earnings - **Lease liabilities and right-of-use assets** — Balance sheet and operating expense - **Share-based compensation** — Operating expenses and net loss - Product revenue is recognized on shipment, so timing of orders affects quarterly results - Diagnostic testing services are recognized when third-party lab results are completed - Contract manufacturing revenue is recognized as work is performed or progresses - Bad debt estimates matter because the company extends credit to domestic and foreign customers - Inventory reserves and overhead allocation can materially affect gross margin - Lease accounting and right-of-use assets affect balance sheet leverage and expense timing - Share-based compensation and going-concern judgments can affect reported earnings and disclosures --- *Last updated: 2026-08-11T04:46:22.675305+00:00*